These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of arsenic trioxide in acute promyelocytic leukemia. Iland HJ; Seymour JF Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer? Gill H Expert Rev Hematol; 2024 Oct; 17(10):661-667. PubMed ID: 39120131 [TBL] [Abstract][Full Text] [Related]
5. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344 [TBL] [Abstract][Full Text] [Related]
6. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912 [TBL] [Abstract][Full Text] [Related]
7. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
8. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child. Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972 [TBL] [Abstract][Full Text] [Related]
9. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334 [TBL] [Abstract][Full Text] [Related]
10. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Dayyani F; Kantarjian H; O'Brien S; Pierce S; Jones D; Faderl S; Garcia-Manero G; Cortes J; Ravandi F Cancer; 2011 Jan; 117(1):110-5. PubMed ID: 20803607 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Lachaine J; Mathurin K; Barakat S; Couban S Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894 [TBL] [Abstract][Full Text] [Related]
12. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
13. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939 [TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214 [TBL] [Abstract][Full Text] [Related]
15. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661 [TBL] [Abstract][Full Text] [Related]
16. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. Gore SD; Gojo I; Sekeres MA; Morris L; Devetten M; Jamieson K; Redner RL; Arceci R; Owoeye I; Dauses T; Schachter-Tokarz E; Gallagher RE J Clin Oncol; 2010 Feb; 28(6):1047-53. PubMed ID: 20085935 [TBL] [Abstract][Full Text] [Related]
17. Current treatment strategy of acute promyelocytic leukemia. Mi J Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
20. ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia? Breccia M; Cicconi L; Lo-Coco F Curr Opin Hematol; 2014 Mar; 21(2):95-101. PubMed ID: 24434605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]